A California jury has returned a reported $34.21 million verdict in a mesothelioma lawsuit involving allegations of asbestos exposure from consumer talcum powder products. Johnson & Johnson disputes the verdict and says it intends to appeal.
What did the jury find?
According to a November 10 announcement from the plaintiffs’ attorneys, a jury in Alameda County, California, returned a reported $34.21 million verdict in a lawsuit brought by Kevin and Tina Reikes. The lawsuit alleged that Kevin Reikes developed mesothelioma following use of talcum powder products, including Johnson’s Baby Powder. Plaintiffs’ counsel reported that the jury found the product defective and that a failure to warn was a substantial factor in causing his disease.
The attorneys reported an allocation of 40% fault to Johnson & Johnson and 60% to a Dr. Scholl’s product defendant that had settled before trial. Those findings describe the reported outcome of this particular case, not a determination that all talc products contain asbestos.
Does the $34.21 million verdict mean Johnson & Johnson must pay that amount?
No such conclusion can be drawn from the reported total alone. The reported award and the percentage allocation are distinct. California law can treat economic and noneconomic damages differently in multi-defendant cases. Settlement credits, post-trial rulings and appellate review may also affect the eventual judgment.
The signed verdict form and entered judgment have not been independently verified for this report. The reported $34.21 million should not be described as a final amount payable by Johnson & Johnson.
What is Johnson & Johnson’s response?
Johnson & Johnson disputed the plaintiffs’ evidence concerning product use, asbestos and causation in its November 9 statement and announced an intention to appeal. The company maintains that its talc products did not contain asbestos and did not cause cancer. The plaintiffs’ account and the company’s response are competing positions; the reported verdict remains subject to further proceedings.
Why can consumer talc matter in a mesothelioma investigation?
Asbestos exposure investigations should not stop with an employment history. Depending on the evidence, household products and personal routines may also warrant examination. Talc and asbestos minerals can occur in related geological settings, but whether a particular product contained asbestos requires product-specific evidence.
Useful questions include the product and packaging remembered, frequency and years of use, where it was used, mineral sourcing and testing evidence, and what family members recall. A diagnosis alone does not establish exposure to a particular product or legal causation.
For a practical approach, see our personal talc and mesothelioma investigation guide and personal talc history checklist.
Does Johnson & Johnson’s proposed ovarian talc resolution cover mesothelioma?
The company has distinguished its proposed resolution of ovarian cancer talc claims from its continuing mesothelioma docket. Those are not interchangeable categories of litigation. Johnson & Johnson’s securities disclosures also discuss the separate allocation of certain talc liabilities and the history of related bankruptcy proceedings.
That distinction matters for families reading headlines about talc settlements: a proposed ovarian cancer resolution should not be assumed to resolve an individual mesothelioma claim. The precise status and terms of any settlement or restructuring must be checked against current company filings and court orders.
For another example of the intersection between talc allegations and bankruptcy, see our Barretts Minerals litigation report.
What happens next?
Post-trial proceedings and any appeal may clarify the verdict’s final legal effect, damages allocation and judgment status. H&S will continue to monitor original court records for developments. This report does not predict the outcome of any appeal or other talc-related case.
Sources and original statements
- Plaintiffs’ counsel — November 10, 2026 verdict announcement
- Johnson & Johnson — November 9, 2026 statement
- Johnson & Johnson SEC filings — talc litigation disclosures
- National Cancer Institute — asbestos and cancer
Legal and medical information notice: This report is general educational information, not individualized legal or medical advice. The verdict is reported from party statements; the original verdict form and final judgment were not independently verified. Liability, exposure and causation must be evaluated case by case. Prior results do not guarantee a similar outcome. Editorial standards.